Jeroen de Baaij and Joost Hoenderop have received a Dutch Kidney Foundation project entitled "From rare diseases to the general population"
Chronic Kidney Disease (CKD) is a heterogenic group of disorders that has a variety of causes and underlying pathologies. As a result, most of the research in CKD is focused on common pathways rather than the causative factors. By studying rare monogenic disorders, it is possible to increase our understanding of the molecular mechanisms involved in common disorders such as CKD.
Recently, we identified mutations in FAM111A in patients with renal failure, short stature, hypoparathyroidism and hypomagnesemia. This syndrome has been first described in the 1960s and has been named Kenny-Caffey syndrome type 2 (KCS2). Although KCS2 has long been considered as an endocrine disorder, our recent findings show that FAM111A mutations cause renal failure and magnesium wasting. In this Dutch Kidney Foundation project proposal, the role of FAM111A will be studied in KCS2 patients to understand how JAK/STAT signaling contributes to renal failure in the general population.
This research project brings together nephrologists, pediatric nephrologists, pathologists and fundamental researchers from Erasmus MC Rotterdam, Radboudumc Nijmegen and a large international network of collaborators. In this team, we aim to link strong research groups specialized in rare disease together with research teams that are focused on common chronic kidney disease. This approach creates a novel research environment that allows knowledge exchange and collaboration between complementary research lines on rare and common diseases.
Related news items
650,000 Euro funding for research into the phasing out of medication for leukaemia patients30 July 2020
With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.read more
Increased role of patients after bowel cancer treatment30 July 2020
Approximately 14,000 patients get colorectal cancer every year. Almost all patients are operated on and monitored afterwards (follow-up). In 2019 Radboudumc started a new approach to follow-up research after the treatment of stage II/III colorectal cancer.read more
ERC Proof of Concept grant received by Ronald van Rij30 July 2020
Ronald van Rij, theme Infectious diseases and global health, received an ERC (European Research Council) Proof of Concept grant of 150,000 euros, in order to make arbovirus vaccines even safer.read more
Testing medical mouth masks Developed in the Netherlands30 July 2020
Auping and AFPRO developed medical mouth caps which were tested by Integrative Physiology. The results were shared with the producing companies.read more
Hypatia fellowship Call is open30 July 2020
The Hypatia fellowship round with the deadline 31 May has been canceled. Therefore, the next available deadline will be 27 September 2020. Radboudumc researchers are invited to scout young potentials to fill the strategic gaps within the research themes imbedded in RIHS and RIMLS.read more